背景:既往研究表明,中老年人体内组织蛋白酶K水平可通过影响骨密度来干预骨质疏松的发生和发展,但组织蛋白酶家族与其他人群骨密度之间是否存在因果关系仍未知。目的:探讨组织蛋白酶与骨密度的因果关系。方法:从IEU Open GWAS数据库提取...背景:既往研究表明,中老年人体内组织蛋白酶K水平可通过影响骨密度来干预骨质疏松的发生和发展,但组织蛋白酶家族与其他人群骨密度之间是否存在因果关系仍未知。目的:探讨组织蛋白酶与骨密度的因果关系。方法:从IEU Open GWAS数据库提取与8种组织蛋白酶相关的遗传位点作为工具变量,以5个年龄段人群的骨密度作为结局。通过双向孟德尔随机化分析,评估组织蛋白酶与骨密度的因果关系。使用Cochran’s Q检验评估遗传工具变量的异质性,使用MR-Egger截距检验评估多效性,使用留一法评估作为工具变量的单核苷酸多态性对暴露和结局因果关系影响的敏感性。结果与结论:①正向孟德尔随机化的逆方差加权法结果显示,组织蛋白酶H与>45岁且≤60岁人群的骨密度呈负相关[OR(95%CI)=0.965(0.94-0.99),P=0.04],组织蛋白酶Z与>30岁且≤45岁人群的骨密度呈负相关[OR(95%CI)=1.06(1.00-1.11),P=0.03];②敏感性分析结果显示因果关系稳定,MR-Egger截距分析未检测到潜在的水平多效性;③反向孟德尔随机化结果显示,骨密度对组织蛋白酶无显著反向作用;④上述结果证实,组织蛋白酶对部分年龄段人群骨密度会造成影响,可能会增加骨质疏松症的发病风险,应给予更多关注。展开更多
BACKGROUND Gallbladder cancer(GBC)is the most common and aggressive subtype of biliary tract cancer(BTC)and has a poor prognosis.A newly developed regimen of gemcitabine,cisplatin,and durvalumab shows promise for the ...BACKGROUND Gallbladder cancer(GBC)is the most common and aggressive subtype of biliary tract cancer(BTC)and has a poor prognosis.A newly developed regimen of gemcitabine,cisplatin,and durvalumab shows promise for the treatment of advanced BTC.However,the efficacy of this treatment for GBC remains unclear.CASE SUMMARY In this report,we present a case in which the triple-drug regimen exhibited marked effectiveness in treating locally advanced GBC,thus leading to a long-term survival benefit.A 68-year-old man was diagnosed with locally advanced GBC,which rendered him ineligible for curative surgery.Following three cycles of therapy,a partial response was observed.After one year of combined therapy,a clinical complete response was successfully achieved.Subsequent maintenance therapy with durvalumab monotherapy resulted in a disease-free survival of 9 months for the patient.The patient experienced tolerable toxicities of reversible grade 2 nausea and fatigue.Tolerable adverse events were observed in the patient throughout the entirety of the treatment.CONCLUSION The combination of gemcitabine and cisplatin chemotherapy with durvalumab was proven to be an effective treatment approach for advanced GBC,with manageable adverse events.Further research is warranted to substantiate the effectiveness of the combined regimen in the context of GBC.展开更多
文摘背景:既往研究表明,中老年人体内组织蛋白酶K水平可通过影响骨密度来干预骨质疏松的发生和发展,但组织蛋白酶家族与其他人群骨密度之间是否存在因果关系仍未知。目的:探讨组织蛋白酶与骨密度的因果关系。方法:从IEU Open GWAS数据库提取与8种组织蛋白酶相关的遗传位点作为工具变量,以5个年龄段人群的骨密度作为结局。通过双向孟德尔随机化分析,评估组织蛋白酶与骨密度的因果关系。使用Cochran’s Q检验评估遗传工具变量的异质性,使用MR-Egger截距检验评估多效性,使用留一法评估作为工具变量的单核苷酸多态性对暴露和结局因果关系影响的敏感性。结果与结论:①正向孟德尔随机化的逆方差加权法结果显示,组织蛋白酶H与>45岁且≤60岁人群的骨密度呈负相关[OR(95%CI)=0.965(0.94-0.99),P=0.04],组织蛋白酶Z与>30岁且≤45岁人群的骨密度呈负相关[OR(95%CI)=1.06(1.00-1.11),P=0.03];②敏感性分析结果显示因果关系稳定,MR-Egger截距分析未检测到潜在的水平多效性;③反向孟德尔随机化结果显示,骨密度对组织蛋白酶无显著反向作用;④上述结果证实,组织蛋白酶对部分年龄段人群骨密度会造成影响,可能会增加骨质疏松症的发病风险,应给予更多关注。
基金Supported by General Project of Natural Science Foundation of Chongqing,China,No.cstc2021jcyj-msxmX0604Chongqing Doctoral"Through Train"Research Program,China,No.CSTB2022BSXM-JCX0045.
文摘BACKGROUND Gallbladder cancer(GBC)is the most common and aggressive subtype of biliary tract cancer(BTC)and has a poor prognosis.A newly developed regimen of gemcitabine,cisplatin,and durvalumab shows promise for the treatment of advanced BTC.However,the efficacy of this treatment for GBC remains unclear.CASE SUMMARY In this report,we present a case in which the triple-drug regimen exhibited marked effectiveness in treating locally advanced GBC,thus leading to a long-term survival benefit.A 68-year-old man was diagnosed with locally advanced GBC,which rendered him ineligible for curative surgery.Following three cycles of therapy,a partial response was observed.After one year of combined therapy,a clinical complete response was successfully achieved.Subsequent maintenance therapy with durvalumab monotherapy resulted in a disease-free survival of 9 months for the patient.The patient experienced tolerable toxicities of reversible grade 2 nausea and fatigue.Tolerable adverse events were observed in the patient throughout the entirety of the treatment.CONCLUSION The combination of gemcitabine and cisplatin chemotherapy with durvalumab was proven to be an effective treatment approach for advanced GBC,with manageable adverse events.Further research is warranted to substantiate the effectiveness of the combined regimen in the context of GBC.